N4BP1 Inhibitors
Chemical inhibitors of N4BP1 can exert their effects through various cellular signaling pathways. Alsterpaullone acts as a cyclin-dependent kinase (CDK) inhibitor, potentially reducing the phosphorylation events critical for N4BP1's interaction with its targets. Similarly, SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, disrupts JNK signaling, which is vital for the signal transduction roles of N4BP1. SB203580, another inhibitor in this cadre, targets p38 MAP kinase, which is integral to the stress response and apoptosis pathways involving N4BP1. Inhibition of p38 MAPK by SB203580 can impair N4BP1's functionality in these processes. LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can diminish N4BP1's functional activity by impeding upstream signals in cell survival pathways. This disruption can lead to reduced activity of N4BP1 in processes regulated by PI3K/Akt pathways.
Continuing with the theme of pathway-specific inhibition, PD98059 and U0126, as MEK inhibitors, can hinder the ERK/MAPK signaling cascade, thereby potentially impairing N4BP1's role in signal transduction. Gö 6983's broad-spectrum inhibition of protein kinase C (PKC) can disrupt PKC-mediated phosphorylation, which is essential for N4BP1's activity in certain pathways. KN-93, which hampers Ca2+/calmodulin-dependent protein kinase II (CaMKII), can lead to a reduction in N4BP1's role in CaMKII-related signaling pathways. Y-27632, a ROCK inhibitor, can interfere with actin cytoskeleton remodeling processes where N4BP1 may play a role, leading to inhibition of N4BP1's function in cytoskeletal dynamics. BIX 02189, by inhibiting MEK5, can disrupt the MEK5/ERK5 signaling pathway, potentially essential for N4BP1's function, leading to a subsequent decrease in its activity. Lastly, SL327's inhibition of MEK1/2 prevents the phosphorylation necessary for N4BP1's activity in ERK/MAPK-dependent signal transduction processes, thereby inhibiting the functional capacity of N4BP1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a known cyclin-dependent kinase (CDK) inhibitor. N4BP1 has been shown to interact with CDKs. By inhibiting CDKs, Alsterpaullone could reduce the phosphorylation events required for N4BP1 to engage its targets or to be functional. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As a c-Jun N-terminal kinase (JNK) inhibitor, SP600125 can inhibit the JNK signaling pathway. Given that N4BP1 is involved in various signal transduction pathways, inhibition of JNK could impair N4BP1's ability to mediate signal transduction. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, a kinase involved in stress responses and apoptosis. N4BP1 is implicated in such cellular responses, and inhibition of p38 MAPK could thus impair the functional role of N4BP1 in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K is upstream in pathways regulating cell survival where N4BP1 might play a role, inhibition of PI3K could lead to a decrease in N4BP1's functional activity within these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which would impede the ERK/MAPK signaling pathway. N4BP1, having roles in signal transduction, could be functionally impaired by the disruption of this pathway due to reduced downstream signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, would similarly inhibit the PI3K/Akt pathway. By doing so, it could reduce the activity of N4BP1 in any processes that are regulated by this pathway. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a broad-spectrum protein kinase C (PKC) inhibitor. N4BP1's activity is dependent on PKC signaling in certain pathways, and its inhibition could disrupt the phosphorylation and thus the function of N4BP1. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). CaMKII influences numerous cellular functions, and its inhibition could lead to a reduction in N4BP1's role in any related signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the ERK/MAPK pathway. By inhibiting this pathway, U0126 could hinder the phosphorylation events and signaling cascades necessary for N4BP1's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, and by inhibiting Rho-associated protein kinase, it could impair actin cytoskeleton remodeling, a process in which N4BP1 may be implicated, thereby inhibiting N4BP1's function in this pathway. | ||||||